2021/12/28 by Arezoo Gowhari Shabgah, Zaid Mahdi Jaber Al-Obaidi, Heshu Sulaiman Rahman +9
Immunology and Microbiology · Medicine · #Chemokine receptors and signaling #Cytokine Signaling Pathways and Interactions #Immune cells in cancer
paper · pdf · doi:10.1093/cei/uxab039
crossref issued 2021/12/28 · crossref published 2021/12/28 · crossref published-online 2021/12/28 · openalex publication_date 2021/12/28 · crossref created 2022/01/12 · openalex created_date 2022/01/26 · crossref published-print 2022/04/04 · crossref deposited 2023/01/22 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31
Cancer is considered a life-threatening disease, and several factors are involved in its development. Chemokines are small proteins that physiologically exert pivotal roles in lymphoid and non-lymphoid tissues. The imbalance or dysregulation of chemokines has contributed to the development of several diseases, especially cancer. CCL19 is one of the homeostatic chemokines that is abundantly expressed in the thymus and lymph nodes. This chemokine, which primarily regulates immune cell trafficking, is involved in cancer development. Through the induction of anti-tumor immune responses and inhibition of angiogenesis, CCL19 exerts tumor-suppressive functions. In contrast, CCL19 also acts as a tumor-supportive factor by inducing inflammation, cell growth, and metastasis. Moreover, CCL19 dysregulation in several cancers, including colorectal, breast, pancreatic, and lung cancers, has been considered a tumor biomarker for diagnosis and prognosis. Using CCL19-based therapeutic approaches has also been proposed to overcome cancer development. This review will shed more light on the multifarious function of CCL19 in cancer and elucidate its application in diagnosis, prognosis, and even therapy. It is expected that the study of CCL19 in cancer might be promising to broaden our knowledge of cancer development and might introduce novel approaches in cancer management.